SCHEMBL25156901

SCHEMBL25156901

CN1CCN(c2cccc(Nc3ncc4c(-c5cc(F)c6ncnn6c5)c[nH]c4n3)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.51
FLT3 P36888 3/20 0.51
CDK1 P06493 3/20 0.51
CCNB1 P14635 3/20 0.51
CDK7 P50613 3/20 0.51
CCNH P51946 3/20 0.51
CCNE1 P24864 2/20 0.51
MNAT1 P51948 1/20 0.51
CLK2 P49760 1/20 0.48
CLK3 P49761 1/20 0.48
DYRK1A Q13627 1/20 0.48
JAK2 O60674 7/20 0.45
JAK3 P52333 5/20 0.45
PTK2 Q05397 5/20 0.45
CCNA2 P20248 4/20 0.45
CCNT1 O60563 3/20 0.45
CDK9 P50750 3/20 0.45
NTRK1 P04629 1/20 0.43
NTRK3 Q16288 1/20 0.43
NTRK2 Q16620 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30347869 1.00 CDK2 (0.51) CDK2FLT3CDK1CCNB1CDK7
SCHEMBL30347626 0.88 DYRK1A (0.62) CDK2FLT3CDK1CCNB1CDK7
SCHEMBL30347874 0.88 CDK2 (0.51) CDK2FLT3CDK1CCNB1CDK7
SCHEMBL25196515 0.88 DYRK1A (0.62) CDK2FLT3CDK1CCNB1CDK7
SCHEMBL25158080 0.88 CDK2 (0.51) CDK2FLT3CDK1CCNB1CDK7
SCHEMBL25206720 0.87 DYRK1A (0.49) CLK2CLK3DYRK1AJAK2JAK3
SCHEMBL30348901 0.87 DYRK1A (0.49) CLK2CLK3DYRK1AJAK2JAK3
SCHEMBL25214166 0.86 CDK2 (0.53) CDK2FLT3CDK1CCNB1CDK7
SCHEMBL30348240 0.86 CDK2 (0.53) CDK2FLT3CDK1CCNB1CDK7
SCHEMBL25156976 0.86 CDK2 (0.51) CDK2FLT3CDK1CCNB1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US disclosed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 US disclosed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 CDK2 72/4885FLT3 1727/4885CDK1 192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.